%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
110 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-08-06T15:27:17Z
2024-03-29T06:50:25-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T06:50:25-07:00
application/pdf
Heather
2003-557.sept
uuid:2b1b3a71-1dd2-11b2-0a00-190a27bd7200
uuid:2b1b3a74-1dd2-11b2-0a00-880000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
128 0 obj
[132 0 R]
endobj
129 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 50 731.5293 Tm
[(8.)-875.1 (Kremer Jm, Furst DE, )17.7 (W)79.9 (einblatt ME, Blotner SD. Significant)]TJ
1.675 -1.25 Td
[(changes in serum )54.8 (AST)-257.3 (across hepatic histological biopsy grades:)]TJ
0 -1.25 TD
(prospective analysis of 3 cohorts receiving methotrexate therapy for)Tj
T*
(rheumatoid arthritis. J Rheumatol 1996;23:459-61.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (V)110.8 (an Ede )54.8 (AE, Laan RF)79.7 (, Rood MJ, et al. Ef)17.7 (fect of folic or folinic acid)]TJ
1.675 -1.25 Td
[(supplementation on the toxicity and ef)17.7 (ficacy of methotrexate in)]TJ
T*
[(rheumatoid arthritis: a forty-eight week, multicenter)39.7 (, randomized,)]TJ
T*
[(double-blind, placebo-controlled study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;44:1515-24.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Angulo P)110.7 (. Nonalcoholic fatty liver disease. N Engl J Med)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2003;346:1221-31.)Tj
-0.00011 Tc 0.02499 Tw 30.8619 12.5 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Langman G, Hall PM, )17.7 (T)69.9 (odd G. Role of non-alcoholic )]TJ
2.1381 -1.25 Td
[(steatohepatitis in methotrexate-induced liver injury)64.8 (. J Gastroenterol)]TJ
T*
(Hepatol 2001;16:1395-401.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Basaranoglu M, )54.8 (Acbay O, Sonsuz )54.8 (A. )54.8 (A)-220.1 (controlled trial of gemfi-)]TJ
2.175 -1.25 Td
(brozil in the treatment of patients with nonalcoholic steatohepatitis)Tj
T*
([letter]. J Hepatol 1999;31:384.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Mokdad )54.8 (AH, Ford ES, Bowman BA, et al. Prevalence of obesity)64.8 (,)]TJ
2.175 -1.25 Td
(diabetes, and obesity-related health risk factors, 2001. JAMA)Tj
0 Tc 0 Tw T*
(2003;289:76-9.)Tj
ET
0 0 0 1 K
43 71 m
547 71 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 43.5 52.9843 Tm
(Kent, et al: MTX risk factors)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(1731)Tj
ET
0 0 0 0 k
/GS0 gs
95.22 76.6 396.48 -10.83 re
f*
0.5 w
95.22 76.6 396.48 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\r;%eI7&4:O=$gr.:Z=ut09FCrT+*im>\:u8FKR"A]?eYV6hVagRbCG'#(_=qS
is@QY)qXD
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
99 0 obj
<>
endobj
54 0 obj
<>
endobj
50 0 obj
<>
endobj
88 0 obj
<>
endobj
115 0 obj
<>
endobj
49 0 obj
<>
endobj
81 0 obj
<>stream
HU}PSW{ 5FF+"nZ["PDBIB !Gx!1" "XEt_tܭu)ݞ^A;;#ܙ3ww~{1Wqk
$9TщmK9M¹.(,)pĂh jGN*,|'[aH
J"S2Sh$ևaJ&EteHL4JȢSv&P$Wi/N+OaN;:F)FH%mEv?csa1l+aSql}La0[cKX(,93-°+2%˥".n(H̓,Kn,<1ac.{]~#sgиqgi86#t.
Z]CV+/Jk2sbl&U2ULeyF+2~-lM.WSvD;ny 1K\lOFS7G5<%)kl{#pZ_pW?J߲Wwq~YܓԺ3wgXv=YO*~Mt̥hWTWwd3ň%7fiD2+)rsoZKi7U"/+?7%"cSeKPo*;PyfeuuEGpE'qzJ@ ][wz,ϒp'ܔ͎U}K3[@dY(Ci||E˛,X hͫǶ,|qQϦf%1,ȭ5_8t#8zH]6'("-#1Ml<6}ma֖Qwlo8i7jn;]/v]Pu?=]{
0\jWȋ3JWːYhnx2GsФ0>9&]Ε9 Ia
[MK;AvP= `o{(/#)JXWy6Fc`U&狋?y8n'8|zԚ4dyarsY,h:$e'rӹAr%O Dzw?:me X/mL^\)Yn<
hrEW(һk+=Kj9+!ڎt+?Zuw+ŷ*L@$)C8w0<3i
#7\'F"rFQ"s@
04]*g/ sE6/
tG%2( d!&T+G=kUafR[ÒPظnTRzihnA>yTa
R.dE̼&K4,/)tZ<VkTNoH0G能$Q+:`q֠dR,r9NGF&^;Z{ig,ihPMnJv8!.'\V^k`kruMi3ӽqzEi [k-ÊaX:-wdּ9VV#.ME uHKUQ/J%Qk4rx 84gkjjB2.7BDmY:;Jp#@uԥ3^AMYMn;nr`ji}-WuUR P"SH M0$!$$A! *E
Rե"V->fێݩc]
XG]{߹A'DW)[GzR|F CfGs75K'ۄ=wZ1T0{Ɠ'=X`%9BF|v/EtNA gb7L3]T͘P"qVӥ8N *hHYPuԍ_J8Aq' b7A
d]
ZjnY7kM᱔ Xt&
g+,=7O-ހqF(DJnSK8O[?Yݼ=,k Uk#җ'h?Tj*v,TU6wIo籝%Κ+I'd96luM.-zz$r_,Z:M|D!vepuFYt
+M\[Ik0vF8xlC+p+N#C{js_;}鉠F7Y*EIR*Wm`-25IbO-f ː}%